Elite Pharmaceuticals, Inc. (ELTP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Elite Pharmaceuticals, Inc. (Elite) is a specialty pharmaceutical company. It carries out the development of oral sustained and controlled release products. Elite's prime focus lies in the areas of pain management, cardiovascular, infection and allergy. Its product portfolio includes eight commercialized products which are either owned, licensed or contract manufactured including phentermine 37.5mg tablets, Lodrane D, methadone 10mg tablets and hydromorphone hydrochloride 8mg tablets, among others

Elite Pharmaceuticals, Inc. Key Recent Developments

Jun 30, 2014 Elite Pharmaceuticals Reports Financial Results for the Fiscal Year Ended March 31, 2014
May 23, 2014 Elite Pharmaceuticals Announces Results of 2014 Annual Meeting of Shareholders
Mar 10, 2014 Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
Feb 14, 2014 Elite Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2014

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table Of Contents

Elite Pharmaceuticals, Inc. (ELTP) - Financial and Strategic SWOT Analysis Review
Table of Contents



Section 1 - About the Company 6
Elite Pharmaceuticals, Inc. - Key Facts 6
Elite Pharmaceuticals, Inc. - Key Employees 7
Elite Pharmaceuticals, Inc. - Key Employee Biographies 8
Elite Pharmaceuticals, Inc. - Major Products and Services 9
Elite Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data 10
Elite Pharmaceuticals, Inc., Pipeline Products by Therapy Area 10
Elite Pharmaceuticals, Inc., Pipeline Products by Development Phase 11
Elite Pharmaceuticals, Inc. - History 13
Elite Pharmaceuticals, Inc. - Company Statement 15
Elite Pharmaceuticals, Inc. - Locations And Subsidiaries 17
Head Office 17
Other Locations and Subsidiaries 17
Section 2 - Company Analysis 18
Elite Pharmaceuticals, Inc. - Business Description 18
Elite Pharmaceuticals, Inc. - Corporate Strategy 19
Elite Pharmaceuticals, Inc. - SWOT Analysis 20
SWOT Analysis - Overview 20
Elite Pharmaceuticals, Inc. - Strengths 20
Strength - Broad Patent Portfolio 20
Strength - Strategic Agreements 20
Strength - Strong Product Pipeline 20
Elite Pharmaceuticals, Inc. - Weaknesses 20
Weakness - Discontinued Products 20
Elite Pharmaceuticals, Inc. - Opportunities 21
Opportunity - Changing Demographics 21
Opportunity - New products 21
Opportunity - Rising Healthcare Expenditure in the US 21
Elite Pharmaceuticals, Inc. - Threats 21
Threat - Intense Competition 21
Threat - Tightening of FDA's Regulatory Oversight 22
Threat - Uncertain RandD Outcomes 22
Elite Pharmaceuticals, Inc. - Key Competitors 23
Section 3 - Company Financial Ratios 24
Financial Ratios - Capital Market Ratios 24
Financial Ratios - Annual Ratios 25
Performance Chart 27
Financial Performance 27
Financial Ratios - Interim Ratios 28
Financial Ratios - Ratio Charts 29
Section 4 - Company's Lifesciences Financial Deals and Alliances 30
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2008 to YTD 2014 30
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Type, 2008 to YTD 2014 31
Elite Pharmaceuticals, Inc., Recent Deals Summary 32
Section 5 - Company's Recent Developments 33
Jun 30, 2014: Elite Pharmaceuticals Reports Financial Results for the Fiscal Year Ended March 31, 2014 33
May 23, 2014: Elite Pharmaceuticals Announces Results of 2014 Annual Meeting of Shareholders 33
Mar 10, 2014: Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally 34
Feb 14, 2014: Elite Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2014 34
Jan 14, 2014: Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Second Opioid Abuse Deterrent Product 34
Nov 14, 2013: Elite Pharmaceuticals to Host Second Quarter Business Update Call on November 18, 2013 35
Nov 14, 2013: Elite Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2014 35
Sep 03, 2013: Elite Pharmaceuticals Announces Participation at the 15th Annual Rodman and Renshaw Global Investment Conference 36
Aug 15, 2013: Elite Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2014 36
Aug 13, 2013: Elite Pharmaceuticals, Inc. Announces Fiscal Year 2014 First Quarter Conference Call on Thursday, August 15, 2013 36
Section 6 - Appendix 37
Methodology 37
Ratio Definitions 37
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables

Elite Pharmaceuticals, Inc., Key Facts 6
Elite Pharmaceuticals, Inc., Key Employees 7
Elite Pharmaceuticals, Inc., Key Employee Biographies 8
Elite Pharmaceuticals, Inc., Major Products and Services 9
Elite Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area 10
Elite Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage 11
Elite Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase 12
Elite Pharmaceuticals, Inc., History 13
Elite Pharmaceuticals, Inc., Subsidiaries 17
Elite Pharmaceuticals, Inc., Key Competitors 23
Elite Pharmaceuticals, Inc., Ratios based on current share price 24
Elite Pharmaceuticals, Inc., Annual Ratios 25
Elite Pharmaceuticals, Inc., Interim Ratios 28
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2008 to YTD 2014 30
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Type, 2008 to YTD 2014 31
Elite Pharmaceuticals, Inc., Recent Deals Summary 32
Currency Codes 37
Capital Market Ratios 37
Equity Ratios 38
Profitability Ratios 38
Cost Ratios 39
Liquidity Ratios 39
Leverage Ratios 40
Efficiency Ratios 40

List of Figures

Elite Pharmaceuticals, Inc., Pipeline Products by Therapy Area 10
Elite Pharmaceuticals, Inc., Pipeline Products by Development Phase 11
Elite Pharmaceuticals, Inc., Performance Chart (2010 - 2014) 27
Elite Pharmaceuticals, Inc., Ratio Charts 29
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2008 to YTD 2014 30
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals by Type, 2008 to YTD 2014 31

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Metastatic Liver Cancer - Pipeline Review, H1 2015

Metastatic Liver Cancer - Pipeline Review, H1 2015

  • $ 2 000
  • Company report
  • March 2015
  • by Global Markets Direct

Metastatic Liver Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Metastatic Liver Cancer - Pipeline Review, H1 2015’, provides an overview of the Metastatic Liver Cancer’s therapeutic ...

Idiopathic (Essential) Hypertension - Pipeline Review, H1 2015

Idiopathic (Essential) Hypertension - Pipeline Review, H1 2015

  • $ 2 000
  • Company report
  • March 2015
  • by Global Markets Direct

Idiopathic (Essential) Hypertension - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Idiopathic (Essential) Hypertension - Pipeline Review, H1 2015’, provides an overview of the Idiopathic ...

Measles - Pipeline Review, H1 2015

Measles - Pipeline Review, H1 2015

  • $ 2 000
  • Company report
  • March 2015
  • by Global Markets Direct

Measles - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Measles - Pipeline Review, H1 2015’, provides an overview of the Measles’s therapeutic pipeline. This report provides comprehensive ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.